口服脾酪氨酸激酶/Janus激酶抑制剂gusacitinib治疗慢性手部湿疹:随机2期研究结果
这项双盲、安慰剂对照、多中心2期研究将97例慢性手部湿疹患者按1:1:1随机分配至安慰剂或gusacitinib 40 mg或80 mg治疗12周(A部分),B部分至第32周均接受gusacitinib。第16周时80 mg组改良总皮损症状评分较安慰剂显著下降,医师总体评估和手部湿疹严重度指数也明显改善,不良事件包括上呼吸道感染、头痛、恶心和鼻咽炎。
要点
- 第16周80 mg组改良总皮损症状评分下降69.5%(P<.005),安慰剂组下降33.5%。
- 第16周80 mg组医师总体评估改善者占31.3%,安慰剂组为6.3%(P<.05)。
- 80 mg组手部湿疹严重度指数下降73.3%,安慰剂组为21.7%(P<.001)。
核心结论
- Gusacitinib在慢性手部湿疹患者中显示出快速改善,且耐受性良好,需进一步研究。
研究设计与样本
- 双盲、安慰剂对照、多中心2期研究,97例慢性手部湿疹患者按1:1:1随机分配至安慰剂或gusacitinib 40 mg或80 mg治疗12周(A部分),B部分至第32周均接受gusacitinib。
主要发现
- 第16周80 mg组改良总皮损症状评分下降69.5%(P<.005),40 mg组下降49.0%(P=.132),安慰剂组下降33.5%。
- 第16周80 mg组医师总体评估改善者占31.3%,安慰剂组为6.3%(P<.05)。
- 第16周80 mg组手部湿疹严重度指数下降73.3%,安慰剂组为21.7%(P<.001)。
- 80 mg组手部疼痛显著减轻(P<.05)。
- 早在第2周,80 mg组较安慰剂在改良总皮损症状评分(P<.005)、医师总体评估(P=.04)和手部湿疹严重度指数(P<.01)方面即观察到显著下降。
关键数值与推荐
- 第16周80 mg组改良总皮损症状评分下降69.5%(P<.005),40 mg组下降49.0%(P=.132),安慰剂组下降33.5%。
- 第16周80 mg组医师总体评估改善者占31.3%,安慰剂组为6.3%(P<.05)。
- 第16周80 mg组手部湿疹严重度指数下降73.3%,安慰剂组为21.7%(P<.001)。
- 80 mg组手部疼痛显著减轻(P<.05)。
- 第2周80 mg组较安慰剂在改良总皮损症状评分(P<.005)、医师总体评估(P=.04)和手部湿疹严重度指数(P<.01)方面显著下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究(warranting further investigations)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gusacitinib is an oral inhibitor of Janus and Spleen tyrosine kinases. METHODS: The efficacy and safety of gusacitinib were evaluated in a double-blind, placebo-controlled, multicenter, phase 2 study in 97 chronic hand eczema patients randomized (1:1:1) to placebo or gusacitinib (40 or 80 mg) for 12 weeks (part A). Then, in part B (through week 32), the patients received gusacitinib. RESULTS: At week 16, patients receiving 80 mg gusacitinib showed a 69.5% (P <.005) decrease in the modified total lesion-symptom score versus 49.0% for 40 mg (P =.132), and 33.5% for placebo. Considerable improvement in Physician's Global Assessment was seen in 31.3% of patients receiving 80 mg versus 6.3% of placebo (P <.05). A 73.3% decrease in the hand eczema severity index versus placebo (21.7%) occurred in patients receiving 80 mg (P <.001). Patients receiving 80 mg experienced a considerable decrease in hand pain (P <.05). As early as week 2, considerable reductions over placebo in modified total lesion-symptom score (P <.005), Physician's Global Assessment (P =.04), and hand eczema severity index (P <.01) were observed (80 mg gusacitinib). Adverse events included upper respiratory infection, headache, nausea, and nasopharyngitis. CONCLUSIONS: Gusacitinib showed rapid improvement in chronic hand eczema patients and was well tolerated, warranting further investigations.
引用
- Jimenez PA, Sofen HL, Bissonnette R, et al. Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023. PMID: 37094653. doi:10.1016/j.jaad.2023.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。